Target Information

Target General Information

Top

Target ID

T14582 (Former ID: TTDR00158)

Target Name

Mycobacterium Biosynthetic alanine racemase (MycB alr)

Synonyms

D-alanine racemase; Alr; Alanine racemase; AlaR

Click to Show/Hide

Gene Name

MycB alr

Target Type

Successful target

[1]

Disease

[+] 2 Target-related Diseases

Bacterial infection [ICD-11: 1A00-1C4Z]

HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14]

Function

Catalyzes the interconversion of L-alanine and D- alanine. Overexpression due to a natural mutation in the promoter is responsible for mediating resistance to D-cycloserine (DCS) in mycobacteria.

Click to Show/Hide

BioChemical Class

Racemases and epimerases

UniProt ID

ALR_MYCSM

EC Number

EC 5.1.1.1

Sequence

MQTTEPMTPPAPLASAQTVIDLGAIDHNVRVLRELAGSADVMAVVKADAYGHGALPVART
ALAAGAAALGVATIPEALALREGGITAPVLAWLHPPGTDFAPAIAADVEVAVSSRRQLEQ
VTAAAAEVGRTATVTVKVDTGLSRNGVGAADYPEVLDVLRRAQADGAIRVRGLMSHLVHG
DDPENPFNGLQGQRLADMRVYAREHGVDYEVAHLCNSPAAMTRPDLAFEMVRPGISLYGL
SPIPERGDMGLRPAMTLKCPVALVRSVHAGDGVSYGHRWVADRDTTLGLLPIGYADGVYR
ALSGRIDVLIKGRRRRAVGRICMDQFVVDLGPDADDVAVGDDAILFGPGANGEPTAQDWA
ELLDTIHYEVVTSPRGRVTRTYLPAGQQD

Click to Show/Hide

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 1 Approved Drugs

Cycloserine

Drug Info

Approved

Tuberculosis

[2], [3]

Mode of Action

[+] 1 Modes of Action

Inhibitor

[+] 10 Inhibitor drugs

Cycloserine

Drug Info

[1]

3-fluorovinylglycine

Drug Info

[4]

Acetate Ion

Drug Info

[1]

Lysine Nz-Carboxylic Acid

Drug Info

[1]

N-(5'-Phosphopyridoxyl)-D-Alanine

Drug Info

[1]

Propanoic Acid

Drug Info

[1]

Propionate

Drug Info

[5]

Pyridoxamine-5'-Phosphate

Drug Info

[1]

Pyridoxyl-Alanine-5-Phosphate

Drug Info

[1]

Pyridoxyl-N,O-Cycloserylamide-5-Monophosphate

Drug Info

[1]

Different Human System Profiles of Target	Top
Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target. A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020). Human Similarity Proteins

Different Human System Profiles of Target

Top

Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.

A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020).

Human Similarity Proteins

There is no similarity protein (E value < 0.005) for this target

Drug Property Profile of Target

Top

(1) Molecular Weight (mw) based Drug Clustering

(2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering

(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering

(4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering

(5) Rotatable Bond Count (rotbonds) based Drug Clustering

(6) Topological Polar Surface Area (polararea) based Drug Clustering

"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five

References

Top

REF 1

How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

REF 2

Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.

REF 3

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

REF 4

Mechanism-based inactivation of alanine racemase by 3-halovinylglycines. J Biol Chem. 1991 Nov 15;266(32):21657-65.

REF 5

Molecular dynamics studies of alanine racemase: a structural model for drug design. Biopolymers. 2003 Oct;70(2):186-200.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Feng ZHU

Prof. Yuzong CHEN